Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 4/20 | 0.39 |
| ▸ | GSK3B | P49841 | 3/20 | 0.39 |
| ▸ | RIPK1 | Q13546 | 6/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.35 |
| ▸ | KARS1 | Q15046 | 1/20 | 0.34 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.31 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.31 |
| ▸ | PRCP | P42785 | 1/20 | 0.31 |
| ▸ | CLK2 | P49760 | 1/20 | 0.31 |
| ▸ | CLK3 | P49761 | 1/20 | 0.31 |
| ▸ | WNT1 | P04628 | 1/20 | 0.30 |
| ▸ | CYP46A1 | Q9Y6A2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL25258903 | 0.92 | RIPK1 (0.37) | DYRK1AGSK3BRIPK1HRH3 | |
| SCHEMBL31196458 | 0.85 | RIPK1 (0.35) | DYRK1AGSK3BRIPK1KCNK3KDM4E | |
| SCHEMBL31205985 | 0.82 | RIPK1 (0.39) | DYRK1AGSK3BRIPK1HRH3SMYD3 | |
| SCHEMBL25259697 | 0.81 | KDM4E (0.35) | RIPK1KCNK3KDM4ESMYD3 | |
| SCHEMBL31205732 | 0.81 | GSK3B (0.31) | DYRK1AGSK3B | |
| SCHEMBL31200021 | 0.80 | RIPK1 (0.34) | RIPK1KDM4E | |
| SCHEMBL31199972 | 0.79 | RIPK1 (0.38) | DYRK1AGSK3BRIPK1KCNK3KDM4E | |
| SCHEMBL31200061 | 0.78 | RIPK1 (0.35) | RIPK1 | |
| SCHEMBL25816590 | 0.78 | RIPK1 (0.45) | RIPK1HRH3SMYD3 | |
| SCHEMBL31205956 | 0.78 | RIPK1 (0.53) | RIPK1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219937-A1 | ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF | SANOFI (FR) | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219937-A1 | ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF | RIPK1, RIPK4, RIPK2 | DYRK1A 1021/4885GSK3B 479/4885RIPK1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.